O
Owens Rebecca Anne
Researcher at Eli Lilly and Company
Publications - 8
Citations - 2274
Owens Rebecca Anne is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Insulin & Diabetes mellitus. The author has an hindex of 5, co-authored 8 publications receiving 2041 citations.
Papers
More filters
Journal ArticleDOI
FGF-21 as a novel metabolic regulator
Alexei Kharitonenkov,Tatiyana L. Shiyanova,Anja Koester,Amy M. Ford,Radmila Micanovic,Elizabeth Galbreath,George E. Sandusky,Lisa Janine Hammond,Julie S. Moyers,Owens Rebecca Anne,Jesper Gromada,Joseph T. Brozinick,Eric D. Hawkins,Victor J. Wroblewski,De Shan Li,Farrokh Mehrbod,S. Richard Jaskunas,Armen B. Shanafelt +17 more
TL;DR: It is concluded that FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.
Journal ArticleDOI
Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors
Kyle W. Sloop,Julia Xiao-Chun Cao,Angela M. Siesky,Hong Yan Zhang,Diane M. Bodenmiller,Amy L. Cox,Steven J. Jacobs,Julie S. Moyers,Owens Rebecca Anne,Aaron D. Showalter,Martin B. Brenner,Achim Raap,Jesper Gromada,Brian R. Berridge,David Monteith,Niels Pørksen,Robert Mckay,Brett P. Monia,Sanjay Bhanot,Lynnetta Watts,M. Dodson Michael +20 more
TL;DR: Together, these studies identify a novel mechanism whereby GCGR inhibitors reverse the diabetes phenotype by the dual action of decreasing hepatic glucose production and improving pancreatic beta cell function.
Journal ArticleDOI
Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.
Thomas A. Engler,Henry,Sushant Malhotra,Brian Eugene Cunningham,Kelly Wayne Furness,Joseph T. Brozinick,Burkholder Timothy P,Michael P. Clay,Joshua Ryan Clayton,Clive Gideon Diefenbacher,Eric D. Hawkins,Philip W. Iversen,YiHong Burlingame Li,Terry D. Lindstrom,Angela Lynn Marquart,Mclean Johnathan Alexander,David Mendel,Elizabeth A. Misener,Daniel A. Briere,O'toole John Cunningham,Warren J. Porter,Queener S,Jon K. Reel,Owens Rebecca Anne,Richard A. Brier,Thomas E Eessalu,Wagner,Robert M. Campbell,Vaughn R +28 more
TL;DR: A series of potent and selective GSK3 inhibitors are discovered, 7-12 show oral activity in an in vivo model of type II diabetes, and 9 and 12 have desirable PK properties.
Patent
Rapid synthesis and screening of peptide mimetics
TL;DR: In this article, a method for the rapid synthesis of very large numbers of peptides which can be integrated with the screening of these peptides as heterogeneous mixtures to identify the specific peptides that demonstrate biological activity using a small number of coupling steps.
Journal ArticleDOI
In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog
Owens Rebecca Anne,Ryan John Hansen,Steven D. Kahl,Chen Zhang,Xiaoping Ruan,Anja Koester,Shun Li,Hui-Rong Qian,Mark W. Farmen,M. Dodson Michael,Julie S. Moyers,Gordon B. Cutler,Andrew Mark Vick,John Michael Beals +13 more
TL;DR: BIL exhibited reduced binding affinity and functional potency as compared with insulin lispro and demonstrated greater selectivity for the human insulin receptor (hIR) asCompared with thehuman insulin-like growth factor 1 receptor.